Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
|
|
TFF Pharmaceuticals, Inc. (TFFP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
8-K
| Quarterly results|
Docs:
|
"UNDERWRITING AGREEMENT",
"OPINION OF GREENBERG TRAURIG, LLP",
"TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock FORT WORTH, Texas, August 14, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or a...",
"TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock FORT WORTH, Texas, August 15, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it has priced its underwritten public offering of 19,896,000 shares of its common stock at a public offering price of $0.25 per share. All of the securities in the underwritten public offering are to be sold by the Company. The Company expects the gross proceeds from this offering to be $4.97 million, before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriter a 30-day option to purchase up to 2,984,400 add...",
"TFF PHARMACEUTICALS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Grant revenue $ 333,351 $ 28,004 $ 384,780 $ 95,439 Operating expenses: Research and development 2,681,898 5,102,090 6,700,557 10,339,514 General and administrative 2,670,363 3,678,119 5,789,579 6,891,317 Total operating expenses 5,352,261 8,780,209 12,490,136 17,230,831 Loss from operations Other income : Interest income 36,120 5,880 71,199 13,065 Change in fair value of note receivable - - Total other income , net 5,880 33,783 13,065 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 36,193,085 25,373,706 36,193,085 25,372,749 5 TFF PHARMACEUTICALS, INC. CON...",
"THE COMPANY'S CORPORATE UPDATE AND PRESENTATION MATERIALS" |
|
| 05/11/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
8-K
| Investor presentation, Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 03/10/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/13/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results |
| 03/26/2020 |
8-K
| Quarterly results |
|
|